Navigation Links
Oncolytics Biotech(R) Inc. Announces Unit Offering
Date:11/17/2009

ks and uncertainties include, among others, the pricing and completion of the contemplated offering, availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

SOURCE Oncolytics Biotech Inc.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
3. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
5. Oncolytics Biotech(R) Inc. Announces Investment in Private Biotechnology Company
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering Europe
7. Oncolytics Biotech(R) Inc. Accelerates Warrant Expiry Date
8. Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
9. Oncolytics Biotech(R) Inc. Announces Phase 3 Update Conference Call
10. Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial
11. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman Renshaw 11th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015 GOJO, inventors ... its commitment to antibiotic stewardship at the White House ... and animal health organizations and stakeholders at the White ... years to slow the emergence of antibiotic-resistant bacteria, detect ... and prevent the spread of resistant infections. ...
(Date:6/2/2015)... CA (PRWEB) June 02, 2015 German-based ... official United States distributor for the Moenninghoff product ... stated, “I am pleased to announce that the R.M. ... market. For our firm, founded in 1916, this is ... R.M. Hoffman is the kind of professional distributor we ...
(Date:6/1/2015)...  Turing Pharmaceuticals AG announced that life sciences executive ... MSc,  has joined the company as president of ... holds a medical degree as well as a ... accomplishments in the pharmaceutical industry, and extensive clinical ... played a leadership role in numerous programs for ...
(Date:6/1/2015)... CHICAGO and RARITAN, N.J. ... & Development, LLC (Janssen) announced data from the ... significant improvement in progression-free survival (PFS) with trabectedin ... with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously ... additional chemotherapy regimen. SAR3007 is the largest randomized ...
Breaking Biology Technology:GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 2GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 3GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 4R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6
... Francis S. Collins, M.D., Ph.D. a,physician-geneticist and ... been named,recipient of the inaugural Inamori Ethics ... and Excellence at Case Western Reserve,University., ... Inamori Ethics Prize honors outstanding international ethical,leaders. ...
... stem cells, NEW YORK, April 9, 2008 ... and a leading developer of,oncology compounds directed to ... completed a $12.5 million round of financing with ... Stemline,s CEO, Ivan Bergstein, MD, said. "We are ...
... Demonstrating Efficacy for Delayed, Chemotherapy-Induced Nausea and Vomiting, According to ... ... WALTHAM, Mass., April 9, 2008 Decision Resources, one,of the world,s ... the regimen of Merck,s Emend for,Injection/Ivemend combined with 5-HT3 RA, is ...
Cached Biology Technology:Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 2Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 3Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 4New Therapy by Merck is Positioned to Earn Gold-Standard Status by 2011 in the Treatment of Chemotherapy-Induced Nausea and Vomiting 2New Therapy by Merck is Positioned to Earn Gold-Standard Status by 2011 in the Treatment of Chemotherapy-Induced Nausea and Vomiting 3
(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... way to synthesize a cancer-killing compound called rasfonin in enough ... fungus discovered clinging to the walls of a New Zealand ... leaving healthy cells untouched. , "In 2000, scientists in Japan ... a prototype anticancer agent, but no one has been able ...
... lung tumors in some human patients just 3-4 months ... University of Pittsburgh Medical Center will report in early ... Association of Physicists in Medicine in Orlando. Although ... effectiveness, Ozhasoglu and his colleagues find promise in this ...
... Institute-led team has identified a molecule that plays a ... each side of the adult brain. , QBI ... her group's research provided new clues regarding development of ... shuttles information between the left and right hemispheres of ...
Cached Biology News:New lab technique churns out fungus' potential cancer fighter 2Radiation-armed robot rapidly destroys human lung tumors 2
... Express Cloning Checker Kits provide two highly ... transformation without time-consuming plasmid preparation. By using ... all you need to do is to ... directly from the transformation plates into the ...
Recombinant Equine IL-4, CF...
DALT GRADIENT MAKER,230V, 1 EA. Category: 2D DALT Systems....
delta-like 1 homolog (Drosophila)...
Biology Products: